PALO ALTO, Calif., November 1, 2018 — Sciton®, a leading manufacturer of high-quality laser and light systems in the medical and aesthetic market is excited to announce the publication of a new multi-center clinical study “Hybrid Fractional Laser: A Multi-Center Trial on the Safety and Efficacy for Photorejuvenation”. The paper will be published in the November issue of the Journal of Drugs in Dermatology (JDD) in a special issue for lasers, light sources, and devices. The study is authored by world-renowned physicians Jill Waibel, MD, Christopher W. Robb, MD, Elizabeth Tanzi, MD, and Jason Pozner, MD.
This study further proves that the HALO™ Hybrid Fractional Laser offers a safe and effective treatment for a multitude of skin conditions on the face and neck while giving patients the results they desire with limited downtime.” Jill Waibel, MD Miami Dermatology and Laser Institute
“We are proud to offer our customers, patients, and business partners substantial clinical evidence that the HALO Hybrid Fractional Laser delivers high patient satisfaction, results they demand, and with the minimal downtime they expect.” Lacee J. Naik, Director of Global Marketing
About HALO Hybrid Fractional Laser
HALO, the world’s first Hybrid Fractional Laser, applies tunable non-ablative (1470nm) and ablative (2940nm) wavelengths to the same microscopic treatment zone to maximize results and reduce downtime. Sciton’s new technology produces targeted, reproducible, effective results that improve the appearance of numerous skin conditions. Intelligent energy delivery, combined with Dynamic Thermal Optimization, ensures precise, even, safe treatments. HALO owners love achieving maximum return on their investment while exceeding their patients’ expectations. Easy to use and virtually painless, HALO sets the standard for the future of laser resurfacing by providing a safe and powerful long-term hybrid solution. As part of the multifaceted, expandable JOULE platform, HALO provides the practitioner with a dynamic and essential component of their aesthetic toolbox.
Sciton, Inc., located in Palo Alto, California, is a totally employee-owned medical device company established in 1997 by co-founders Jim Hobart, Ph.D., and Dan Negus, Ph.D. Sciton is committed to providing best-in-class laser and light solutions for medical professionals who want superior durability, performance, and value. Sciton offers aesthetic and medical devices for women’s health, fractional and full-coverage skin resurfacing and skin revitalization, phototherapy, vascular and pigmentation lesions, scar reduction, acne, body contouring, and hair reduction. Sciton operates worldwide with direct sales forces in the United States, Canada, Japan, Australia, and distributor partners in more than 45 countries. For more information and a complete listing of Sciton systems, visit scitonlasers.ca.